Biomega was founded in 2000 on the premise of advancing innovative biotechnology to release the full nutritional and functional value of otherwise underutilized side streams from the salmon industry. Today, Biomega has a rich patent family of various technologies, with the continuous enzymatic hydrolysis process at its core. Biomega invests continuously in innovation through R&D to ensure best-in-class technology and respond to customers’ needs, including product development, traceability and sustainability.
In our modern biorefineries we turn food-grade fresh raw materials into premium feed and food-grade ingredients. Sophisticated biorefining processes ensure careful separation of nutritional components. Local and fresh raw materials guarantee stabile supply to our customers around the world.
The acquisition of Biomega by AMERRA Capital in 2017 has allowed the company to release its full growth potential. Biomega is now aiming to increase its number of production facilities by entering into strategic partnerships with raw material providers. This is not only limited to salmon, but also includes other marine species such as cod, pelagic and mesopelagic, as well as chicken and other types of poultry.
Biomega aspires to become the leading partner for innovative high-quality ingredients to the health and nutrition industry.
